[go: up one dir, main page]

WO2023113111A1 - Composition de blanchiment de la peau pour soulager le mélasme, les taches de vieillesse, etc. à l'aide d'une gomme mastic soluble dans l'eau - Google Patents

Composition de blanchiment de la peau pour soulager le mélasme, les taches de vieillesse, etc. à l'aide d'une gomme mastic soluble dans l'eau Download PDF

Info

Publication number
WO2023113111A1
WO2023113111A1 PCT/KR2022/005152 KR2022005152W WO2023113111A1 WO 2023113111 A1 WO2023113111 A1 WO 2023113111A1 KR 2022005152 W KR2022005152 W KR 2022005152W WO 2023113111 A1 WO2023113111 A1 WO 2023113111A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
water
mastic gum
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/005152
Other languages
English (en)
Korean (ko)
Inventor
심태진
김지훈
홍인기
김종필
이경민
정정일
김문정
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frombio Co Ltd
Original Assignee
Frombio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frombio Co Ltd filed Critical Frombio Co Ltd
Priority to CN202280005643.8A priority Critical patent/CN116710040A/zh
Publication of WO2023113111A1 publication Critical patent/WO2023113111A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a skin whitening composition for improving melasma, age spots, etc. using water-soluble mastic gum.
  • Melanin present in the basal layer of the epidermis is a major pigment that determines skin color and plays a role in protecting the skin by preventing damage caused by ultraviolet rays and removing active oxygen.
  • melanin when melanin is locally overproduced, it causes skin diseases such as melasma, freckles, dark spots, and skin cancer.
  • melanin when continuously overproduced melanin stays in the dermis, it turns the skin color black or dull, increasing the desire for whitening (Pigment Cell Res. 2007 Feb;20(1):2-13.; Curr Biol. 2011 Nov. 22;21(22):1906-11.; Ann Dermatol Venereol.
  • Melanin is a phenolic polymeric natural pigment widely present in living organisms. In the human body, it is synthesized in melanosomes in melanocytes in the basal layer of the epidermis, and is transferred to surrounding keratinocytes to show human skin color. When melanin is abnormally low, skin lesions such as vitiligo are induced, and when it is produced in excess, on the contrary, acquired hyperpigmentation such as melanoderma, postinflammatory melanoderma, and solar lentigo A variety of skin diseases, including
  • melanogenesis A series of processes in which melanin is synthesized are collectively referred to as melanogenesis.
  • Melanin production uses tyrosine, one of the amino acids, as a substrate, and DOPA (3, After conversion to DOPA quinone through 4-dihydroxyphenylalanine), melanin is synthesized by polymerization with amino acids or proteins after undergoing a non-enzymatic reaction and spontaneous oxidation process (Korean J. FOOD SCI. TECHNOL., 2000. 32(3):736;Journal of Life Science, 2013.23(12):1445;Pigment Cell Res.1999.12(1):4-12.).
  • cAMP cyclic monophosphate/protein kinase A
  • CREB1 cAMP responsive element binding protein 1
  • MITF plays an important role in melanin synthesis.
  • cAMP cyclic monophosphate/protein kinase A
  • PKA cyclic monophosphate/protein kinase A
  • MITF plays an important role in melanin synthesis.
  • arbutin and kojic acid are a tyrosine antagonist, and kojic acid chelates the active site of tyrosinase to inhibit the process of tyrosine to dopa and dopaquinone.
  • arbutin and kojic acid are known to have strong whitening effects, due to some side effects such as skin irritation, studies are being actively conducted to find substances having whitening activity from natural substances with relatively few side effects.
  • Astringent action is a phenomenon in which skin proteins form cross-links with high-molecular flavonoids, resulting in skin contraction.
  • the contraction action contracts skin and mucosal blood vessels, suppresses the secretion of mucus in the cell and lymphatic gaps, forms a sparingly soluble film on the surface of the skin and mucous membranes to protect local areas, and maintains elasticity by making tissues dense. It also functions to reduce cell membrane permeability. As such, the convergence effect can be said to give a sense of elasticity and flexibility to the skin by contracting excessively open pores or pores.
  • the present invention discloses the skin whitening activity and skin astringent activity of water-soluble mastic gum.
  • An object of the present invention is to provide a composition for skin whitening using water-soluble mastic gum.
  • Another object of the present invention is to provide a composition for improving skin convergence using water-soluble mastic gum.
  • the present invention does not show any particular cytotoxicity to CCD-986sk cells, which is a human fibroblast cell, while water-soluble mastic gum does not show tyrosina It was completed by suppressing the expression of the enzyme gene and confirming that it has a high binding force with hemoglobin protein.
  • the present invention can be identified as a skin peeling composition containing water-soluble mastic gum as an active ingredient, and in another aspect, skin convergence improvement containing water-soluble mastic gum as an active ingredient. composition can be identified.
  • water-soluble mastic gum is a suspension obtained by suspending mastic gum in water as a solvent by converting mastic gum into fine particles (average particle diameter in the range of 1 to 999 ⁇ m) or nanoparticles (average particle diameter in the range of 1 to 999 nm). ) (that is, to maintain a dispersed state without aggregation or precipitation in water as a solvent).
  • Such water-soluble mastic gum can be obtained by pulverizing mastic gum into microparticles or nanoparticles, adding water thereto, stirring, and mixing.
  • suspending agents may be added in appropriate amounts before and after mixing the fine or nanoparticle mastic gum with water and before and after grinding. Any suspending agent known in the art may be used, such as gum arabic, tragacanth gum, agar, karaya gum, and locust bean gum.
  • guar gum guar gum
  • xanthan gum xanthan gum
  • ghatti gum water-soluble polymers such as pectin, cyclodextrin, glycerin or its fatty acid ester derivatives, methylcellulose or hydrogel Modified cellulose such as oxymethyl cellulose, various surfactants, and the like can be used.
  • These suspending agents may be used alone or in combination of two or more, and may be used in an appropriate amount for suspending, specifically, in the range of 20 to 200 parts by weight based on 100 parts by weight of mastic gum.
  • water-soluble mastic gum refer to the following examples, or Korean Registered Patent No.
  • mastic gum refers to a resin obtained from a mastic tree ( Pistacia lentiscus ).
  • active ingredient means a component that exhibits the desired activity alone or can exhibit activity in combination with a carrier having no activity itself.
  • the composition of the present invention may contain the active ingredient in any amount (effective amount) as long as it can exhibit skin whitening activity, skin astringent activity, etc. depending on the product, formulation, etc., and a typical effective amount is based on the total weight of the composition. When it will be determined within the range of 0.001% by weight to 15% by weight.
  • effective amount means that when the composition of the present invention is administered to a mammal, preferably a human, to which it is applied, during the administration period according to the advice of medical experts, skin experts, etc., the intended medical / It refers to the amount of the active ingredient included in the composition of the present invention that can exhibit a dermatological effect. Such an effective amount can be determined empirically within the ordinary ability of one skilled in the art.
  • the composition of the present invention is used for skin whitening effect, skin convergence improvement effect, skin wrinkle improvement activity, skin hypersensitivity reaction inhibition activity, skin protection activity (inhibition of skin damage by ultraviolet rays, skin moisturizing) Etc.), etc.), etc., in order to enhance the convenience of intake, intake, and use, any compound or natural extract known to have a corresponding activity and whose safety has already been verified in the art may be additionally included. .
  • These compounds or extracts include each country's Pharmacopoeia (Korean Pharmacopoeia), each country's Health Functional Food Codex (in Korea, the Ministry of Food and Drug Safety, "Health Functional Food Standards and Specifications”), and each country's Functional Cosmetics Codex (in Korea, the Ministry of Food and Drug Safety, Functional cosmetics standards and test methods”), compounds or extracts that have been approved as items under the laws of each country governing the manufacture and sale of pharmaceuticals (“Pharmaceutical Affairs Act” in Korea), and health functional foods
  • the laws of each country regulating the manufacture and sale of compounds or extracts whose functionality has been recognized the laws of each country regulating the manufacture and sale of compounds or extracts whose functionality has been recognized
  • the laws of each country regulating the manufacture and sale of functional cosmetics the ⁇ Cosmetics Act ⁇ in Korea
  • compounds or extracts whose functionality has been recognized are included.
  • These ingredients include, for example, retinol, retinyl palmitate, adenosine, and polyethoxylease recognized as skin wrinkle improvement ingredients in the Cosmetics Codex (Korean Ministry of Food and Drug Safety notification, ⁇ Standards and Test Methods for Functional Cosmetics ⁇ ) under the Korean ⁇ Cosmetics Act ⁇ . tidamide, etc., and drometrizol, drometrizoletrisiloxane, digaloyltrioleate, dimethicodyethylbenzalmalonate, diethylhexylbutamidotriazone, etc. recognized as UV protection ingredients in the Korean Cosmetics Codex.
  • UV protection ingredients according to the Korea Health Functional Food Act, green tea extract, bamboo leaf extract, melon extract, raspberry extract, beeswax alcohol, ubiquinol, coenzyme Q10, tomato extract, grape seed extract, French maritime pine bark extract, red ginseng concentrate, etc., and also improve sensitive skin conditions according to the Korean Health Functional Food Act.
  • L. sakei Probio 65 recognized as a functional ingredient, gamma-linolenic acid-containing oil, L.plantarum CJLP133, a lactic acid bacterium derived from fruits and vegetables, and probiotics ATP.
  • One or more of these compounds or natural extracts may be included in the composition of the present invention together with the active ingredient.
  • the skin composition of the present invention can be identified as a cosmetic composition.
  • the cosmetic composition may be classified as an arbitrary product in terms of its use and law, and specifically, may be a functional cosmetic having a purpose such as skin whitening, a non-functional general cosmetic, and the like.
  • product form it may take any product form, specifically, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax It can be formulated as a foundation, spray, and the like.
  • it may be a softening lotion, nutrient lotion, nutrient cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, or powder formulation.
  • the cosmetic composition of the present invention may include, in addition to the active ingredient, ingredients commonly used in cosmetic compositions, for example, stabilizers, solubilizers, surfactants, vitamins, conventional adjuvants such as pigments and fragrances, and carriers.
  • ingredients commonly used in cosmetic compositions for example, stabilizers, solubilizers, surfactants, vitamins, conventional adjuvants such as pigments and fragrances, and carriers.
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.
  • a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol, fatty acid esters of sorbitan, and the like can be used.
  • the formulation of the present invention is a suspension
  • a liquid diluent such as water, ethanol or propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene sorbitan ester, microcrystals
  • Acidic cellulose, aluminum metahydroxide, bentonite, agar, and the like may be used.
  • the formulation of the present invention is surfactant-containing cleansing
  • carrier components aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether Sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • the cosmetic composition of the present invention may be prepared according to a method for preparing a cosmetic composition conventionally performed in the art, except for including an active ingredient exhibiting skin whitening activity.
  • composition of the present invention can be regarded as a food composition.
  • the food composition of the present invention can be prepared in any form, for example, beverages such as tea, juice, carbonated beverages, and ionic beverages, processed oils such as milk and yogurt, chewing gum, rice cakes, traditional Korean snacks, bread, snacks, noodles, etc. It can be manufactured into health functional food preparations such as foods, tablets, capsules, pills, granules, liquid, powder, flakes, pastes, syrups, gels, jellies, and bars.
  • the food composition of the present invention may take any product classification as long as it conforms to the enforcement regulations at the time of manufacture and distribution in legal and functional classification.
  • health functional food according to the Korean ⁇ Health Functional Food Act ⁇ , or confectionery, legumes, teas, and beverages according to each food type according to the Food Code (MFDS notification ⁇ Food Standards and Specifications ⁇ ) of the Korea ⁇ Food Sanitation Act ⁇ , special purpose foods, etc.
  • MFDS notification ⁇ Food Standards and Specifications ⁇
  • special purpose foods etc.
  • the food composition of the present invention may include food additives in addition to the active ingredient.
  • Food additives may generally be understood as substances that are added to, mixed with, or infiltrated into food in manufacturing, processing, or preserving food. Since food is consumed daily and for a long period of time, its safety must be guaranteed.
  • Food Additives Code under the laws of each country regulating the manufacture and distribution of food (the ⁇ Food Sanitation Act ⁇ in Korea), food additives with guaranteed safety are limitedly regulated in terms of ingredients or functions.
  • Korean Food Additives Codex MFDS notification ⁇ Standards and Specifications for Food Additives ⁇
  • food additives are classified into chemical synthetic products, natural additives and mixed preparations in terms of ingredients and are regulated. It is divided into additives, preservatives, emulsifiers, acidulants, and thickeners.
  • Sweeteners are used to impart appropriate sweetness to foods, and both natural and synthetic sweeteners can be used in the composition of the present invention.
  • a natural sweetener is used, and examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.
  • Flavors may be used to improve taste or aroma, and both natural and synthetic flavors may be used. Preferably, it is the case of using a natural one. In case of using natural ones, in addition to flavor, the purpose of enhancing nutrition can also be combined.
  • a natural flavoring agent it may be obtained from apples, lemons, tangerines, grapes, strawberries, peaches, etc., or obtained from green tea leaves, roundworms, bamboo leaves, cinnamon, chrysanthemum leaves, jasmine, and the like.
  • those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, ginkgo, etc. can be used.
  • Natural flavors can be liquid concentrates or solid extracts. In some cases, synthetic flavors may be used, and synthetic flavors may include esters, alcohols, aldehydes, terpenes, and the like.
  • Calcium sorbate, sodium sorbate, potassium sorbate, calcium sorbate, sodium benzoate, potassium benzoate, ethylenediaminetetraacetic acid (EDTA), etc. may be used as preservatives, and as emulsifiers, gum arabic, carboxymethylcellulose, xanthan gum, pectin and the like, and as the acidulant, acidulic acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, and the like may be used.
  • Acidulants may be added to the food composition to have an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to improving taste.
  • a suspending agent As the thickening agent, a suspending agent, a sedimentation agent, a gel forming agent, a swelling agent, and the like may be used.
  • the food composition of the present invention may include physiologically active substances or minerals known in the art and guaranteed to be stable as food additives for the purpose of supplementing or reinforcing functionality and nutrition.
  • physiologically active substances include catechins contained in green tea, vitamins such as vitamin B1, vitamin C, vitamin E, and vitamin B12, tocopherol, dibenzoylthiamine, and the like.
  • minerals include calcium preparations such as calcium citrate and magnesium stearate. magnesium preparations such as the like, iron preparations such as iron citrate, chromium chloride, potassium iodine, selenium, germanium, vanadium, zinc, and the like.
  • the food composition of the present invention may include the above-mentioned food additives in an appropriate amount to achieve the purpose of addition according to the type of product.
  • composition for skin whitening of the present invention can be understood as a pharmaceutical composition.
  • the target disease can be understood as skin hyperpigmentation, and specific examples of such hyperpigmentation include freckles, senile spots, liver spots, melasma, brown or dark spots, solar pigment Melasma blue, hyperpigmentation after the use of drugs such as calcium antagonists, hyperpigmentation sequelae following tissue sclerotherapy, brown spots of pregnancy, melasma in women taking oral contraceptives, wounds or dermatitis including scratches and burns may include, but are not limited to, post-inflammatory hyperpigmentation, phototoxic reaction, or other similar small fixed pigmented lesions.
  • the pharmaceutical composition of the present invention may be formulated into an oral dosage form or a parenteral dosage form according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient.
  • the route of administration herein may be any appropriate route including topical route, oral route, intravenous route, intramuscular route, and direct absorption through mucosal tissue, and two or more routes may be used in combination.
  • An example of a combination of two or more routes is a case in which two or more formulations of drugs are combined according to the route of administration, for example, one drug is firstly administered intravenously and the other drug is secondly administered through a topical route.
  • Pharmaceutically acceptable carriers are well known in the art depending on the route of administration or dosage form, and specific reference may be made to the pharmacopoeia of each country including the "Korean Pharmacopoeia”.
  • the pharmaceutical composition of the present invention is prepared as an oral dosage form, powder, granule, tablet, pill, dragee, capsule, liquid, gel, syrup, suspension, wafer according to a method known in the art together with a suitable carrier.
  • suitable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol and xylitol, starches such as corn starch, potato starch and wheat starch, cellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, Celluloses such as hydroxypropylmethylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable oil, ethanol, glycerol etc.
  • binders include starch, magnesium aluminum silicate, starch ferrite, gelatin, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, glucose, corn sweetener, sodium alginate, polyethylene glycol, wax and the like, and oleic acid as a lubricant Sodium, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, magnesium salts and calcium salts thereof, polyethylene glycol, and the like, and disintegrants include starch, methyl cellulose , agar, bentonite, xanthan gum, starch, alginic acid or its sodium salt, and the like.
  • the pharmaceutical composition of the present invention when prepared as a parenteral formulation, it may be formulated in the form of an injection, transdermal administration, nasal inhalation, and suppository along with a suitable carrier according to a method known in the art.
  • a suitable carrier When formulated as an injection, an aqueous isotonic solution or suspension may be used as a suitable carrier, and specifically, an isotonic solution such as phosphate buffered saline (PBS) containing triethanolamine, sterile water for injection, or 5% dextrose may be used.
  • PBS phosphate buffered saline
  • transdermal formulation When formulated as a transdermal formulation, it may be formulated in the form of ointments, creams, lotions, gels, external solutions, pastas, liniments, air rolls, and the like.
  • a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc.
  • the carrier when formulated as a suppository, the carrier is Witepsol ( witepsol), tween 61, polyethylene glycols, cacao fat, laurin fat, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, sorbitan fatty acid esters, and the like can be used.
  • the preferred dosage of the pharmaceutical composition of the present invention is in the range of 0.001 mg/kg to 10 g/kg per day, preferably 0.001 mg/kg to 10 g/kg, depending on the patient's condition, body weight, sex, age, severity of the patient, and route of administration. It may be in the range of 1 g/kg. Administration can be done once a day or divided into several times. These dosages should not be construed as limiting the scope of the present invention in any respect.
  • composition of the present invention can be commercialized as cosmetics, food, medicine, and the like.
  • 3 is a skin astringent activity measurement result through the degree of binding to hemoglobin.
  • Mastic gum powder was visually inspected to confirm color and inspect for foreign substances. Afterwards, 20% by weight of mastic gum powder, 75.7% by weight of purified water, 4% by weight of cyclodextrin, and 0.3% by weight of additives (ghatti gum) were added and heated at 30 to 50 ° C using a homomixer (KNS Co., Ltd.). was dispersed at 2,000 to 3,000 rpm for 30 to 60 minutes to a particle size of about 20 to 50 ⁇ m. The dispersion of the mastic gum was carried out using a bead mill (DNTech Co., Ltd.) at 20 to 40 ° C. for 3 to 6 hours so that the final dispersed particles had an average size of 600 to 1,000 nm. Thereafter, the mixture was filtered through a 40 to 60 ⁇ m housing filter to obtain an aqueous solution of mastic gum in a suspension state. In the following experiments, this water-soluble mastic gum was used as it is.
  • a homomixer K
  • CCD-986sk cells which are human fibroblasts, were subcultured at ATCC (Manassas, VA, USA) and frozen in cryovials. After dissolving this in a water bath, penicillin (100 U/ml), streptomycin (100 ug/ml), and 10% heat-inactivated serum were added to DMEM (Dulbecco's Modified Eagle's Medium) at 95% air, 5% CO 2 and 37°C. cultured with. When the CCD-986sk cells adhered to the culture dish and the cells grew, the cells were collected using 0.25% trypsin/10 mM EDTA, divided at a ratio of 1:3, and maintained in 10% DMEM to culture the cells.
  • ATCC Manassas, VA, USA
  • CCK-8 The reagent used in the experiment, was purchased from Dongin Biotech Co., Ltd. (Seoul, Korea).
  • CCD-986sk cells were treated in 96-well plates at a concentration of 1 ⁇ 10 3 cells/well by 100 ul and then cultured for 24 hours. When the cells attached to the bottom, the example samples were treated for 24 hours up to 2 mg/mL. After incubation for 4 hours under conditions of 10 ul of CCK-8 reagent and 100 ul of DMEM, absorbance was measured at 540 nm with a spectrophotometer.
  • Example 500 ul each of the sample of Example was prepared for each concentration, mixed with the same amount of 0.1% hemoglobin solution mixed in PBS, mixed for 1 minute (Voltexing), and left at room temperature for 5 minutes. Thereafter, 100 ul each was dispensed into 96-well plates, and absorbance was measured at 405 nm with a spectrophotometer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition pour améliorer le blanchiment de la peau et l'astringence de la peau, la composition réduisant l'expression de gènes de tyrosinase sans présenter de cytotoxicité pour les cellules de CCD-986 sk, qui sont des fibroblastes humains, et utilisant une gomme mastic soluble dans l'eau présentant une capacité de liaison élevée à des protéines d'hémoglobine.
PCT/KR2022/005152 2021-12-17 2022-04-08 Composition de blanchiment de la peau pour soulager le mélasme, les taches de vieillesse, etc. à l'aide d'une gomme mastic soluble dans l'eau Ceased WO2023113111A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280005643.8A CN116710040A (zh) 2021-12-17 2022-04-08 利用水溶性乳香胶的用于改善黄褐斑以及老年斑等的皮肤美白用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210181533A KR102429548B1 (ko) 2021-12-17 2021-12-17 수용화 매스틱 검을 이용한 기미, 검버섯 등의 개선을 위한 피부 미백용 조성물
KR10-2021-0181533 2021-12-17

Publications (1)

Publication Number Publication Date
WO2023113111A1 true WO2023113111A1 (fr) 2023-06-22

Family

ID=82826731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/005152 Ceased WO2023113111A1 (fr) 2021-12-17 2022-04-08 Composition de blanchiment de la peau pour soulager le mélasme, les taches de vieillesse, etc. à l'aide d'une gomme mastic soluble dans l'eau

Country Status (3)

Country Link
KR (2) KR102429548B1 (fr)
CN (1) CN116710040A (fr)
WO (1) WO2023113111A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102603568B1 (ko) * 2023-03-30 2023-11-20 주식회사 프롬바이오 수용화 매스틱 검을 이용한 피부장벽 기능 개선용 조성물
GR1010755B (el) * 2023-06-22 2024-08-28 Μεντιτερρα Ανωνυμη Βιομηχανικη Εμπορικη Συνεταιριστικη Εταιρεια, Υδροφιλη-υδατοδιασπειρομενη λυοφιλιοποιημενη σκονη μαστιχας σε ποσοστο 35-45% φυσικης ρητινης μαστιχας και μεθοδος παραγωγης της
KR102672845B1 (ko) * 2023-08-30 2024-06-05 주식회사 래디안 향상된 피부 미백 효과 및 항산화 효과를 갖는 화장료 조성물 및 이의 제조방법
KR102672844B1 (ko) * 2023-09-08 2024-06-05 주식회사 래디안 피부 장벽 기능 개선, 피부 진정, 피부 재생 및 상처 치유 효과를 갖는 화장료 조성물 및 이의 제조방법
KR102697519B1 (ko) * 2023-12-05 2024-08-22 주식회사 프롬바이오 수용화 매스틱 검을 이용한 지방 유래 줄기세포의 모유두세포로의 분화 유도용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020320A (ko) * 2000-06-30 2003-03-08 유니레버 엔.브이. 매스틱 검을 포함하는 미용 피부 관리 조성물
KR20130138938A (ko) * 2012-06-12 2013-12-20 남창옥 매스틱 추출물을 포함하는 화장품 조성물 및 그 제조방법
KR20180055331A (ko) * 2016-11-17 2018-05-25 주식회사 프롬바이오 나노입자화를 통해 분산력 및 수용화력이 높아진 매스틱 검 수용액 제조방법
KR102328824B1 (ko) * 2021-07-12 2021-11-23 주식회사 프롬바이오 수용화 매스틱 검과 감태나무 추출물을 이용한 발모 촉진 또는 탈모 억제용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309349B (zh) * 2016-09-30 2019-05-14 广东丸美生物技术股份有限公司 一种去黑眼圈及淡化细纹的组合物及其制备方法和应用
KR101971837B1 (ko) * 2018-09-19 2019-04-23 동국제약 주식회사 병풀 부정근 추출물을 유효성분으로 함유하는 피부 미백 및 주름개선용 화장료 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020320A (ko) * 2000-06-30 2003-03-08 유니레버 엔.브이. 매스틱 검을 포함하는 미용 피부 관리 조성물
KR20130138938A (ko) * 2012-06-12 2013-12-20 남창옥 매스틱 추출물을 포함하는 화장품 조성물 및 그 제조방법
KR20180055331A (ko) * 2016-11-17 2018-05-25 주식회사 프롬바이오 나노입자화를 통해 분산력 및 수용화력이 높아진 매스틱 검 수용액 제조방법
KR102328824B1 (ko) * 2021-07-12 2021-11-23 주식회사 프롬바이오 수용화 매스틱 검과 감태나무 추출물을 이용한 발모 촉진 또는 탈모 억제용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIBELLE BIOCHEMISTRY: "Chios mastic – a precious natural remedy – to treat impure skin and large pores", COSMETICS DESIGN-EUROPE.COM, 4 March 2019 (2019-03-04), XP093072068, Retrieved from the Internet <URL:https://www.cosmeticsdesign-europe.com/Headlines/Promotional-Features/Mastic-active-ingredient-oily-skin-pore-refiner-matifying> [retrieved on 20230809] *

Also Published As

Publication number Publication date
KR102488588B1 (ko) 2023-01-18
KR102429548B1 (ko) 2022-08-05
CN116710040A (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
KR102488588B1 (ko) 수용화 매스틱 검을 이용한 피부 미백용 조성물
KR101971837B1 (ko) 병풀 부정근 추출물을 유효성분으로 함유하는 피부 미백 및 주름개선용 화장료 조성물
KR20110098124A (ko) 포제를 이용한 인삼 열매 추출물을 함유하는 조성물
KR20210108911A (ko) 로즈마리 이온성 액체 추출물을 포함하는 항산화 또는 미백용 조성물
KR102301299B1 (ko) 큰도꼬마리 추출물을 이용한 피부 미백용 조성물
KR102218472B1 (ko) 개싱아 추출물을 이용한 피부 미백용 조성물
KR20190036060A (ko) 물여뀌 추출물을 이용한 피부 미백용 조성물
KR102866429B1 (ko) 수용화 커큐민과 밀겨 추출물을 이용한 피부 미백 및 피부 주름 개선용 조성물
KR102128977B1 (ko) 흰꽃여뀌 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
KR101995384B1 (ko) 명월초 발효물을 유효성분으로 함유하는 피부 미백 및 항산화용 조성물
KR20210044952A (ko) 대추씨 발효물을 유효성분으로 포함하는 피부 미백 및 주름 개선용 조성물
KR20200025386A (ko) 순비기나무 정유 추출물을 이용한 피부 주름 개선 또는 피부 미백용 조성물
KR20230033388A (ko) 푸른여로 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
KR102695901B1 (ko) 줄댕강나무 추출물을 이용한 피부 미백용 조성물
KR102846311B1 (ko) 노랑꽃창포 추출물을 이용한 피부 미백용 조성물
KR102510149B1 (ko) 바위수국 추출물을 이용한 피부 미백용 조성물
KR102468186B1 (ko) 벌노랑이 추출물을 이용한 피부 미백용 조성물
KR102615923B1 (ko) 잔사틴을 이용한 피부 미백용 조성물
KR102606796B1 (ko) 콩배나무 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
KR102709766B1 (ko) 한라꽃향유 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
KR102625163B1 (ko) 물박달나무 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
KR102289102B1 (ko) 박새 추출물을 이용한 피부 미백 및 주름 개선용 조성물
WO2017086692A1 (fr) Composition de blanchiment de la peau utilisant un extrait de dipterocarpus intricatus
KR20110036299A (ko) 누룩 추출물을 함유하는 항노화 및 미백용 화장료 조성물
WO2024128333A1 (fr) Composition utilisant un extrait veratrum versicolor pour atténuer les rides de la peau et blanchir la peau

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 202280005643.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22907584

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A 16/10/2024)

122 Ep: pct application non-entry in european phase

Ref document number: 22907584

Country of ref document: EP

Kind code of ref document: A1